• 1. Department of Clinical Epidemiology, The First Hospital of China Medical University, Shenyang 110001, China;2. Department of Clinical Medicine (Seven-Year System), China Medical University, Shenyang 110001, China;3. Department of Laboratory Medicine, Dalian Medical University, Dalian 116001, China;
WANG Hailong, Email: whl604@sohu.com
Export PDF Favorites Scan Get Citation

Objective  To systemically evaluate the accuracy of f/t-PSA for diagnosing prostate cancer with a t-PSA level of 4-10ng/mL through meta-analysis.
Methods  A literature search of CBM, VIP, CNKI and Wanfang Data from 1999 to 2009 was performed. Related journals were also searched manually. Two reviewers independently assessed trial quality according to QUADAS items. Heterogenous studies and meta-analysis were conducted by Meta-Disc1.4 software. The analysis was based on different critical values of f/t-PSA (0.1, 0.15, 0.2, 0.25, and 0.3).
Results  Total 18 studies involving 2217 subjects were included. No threshold effect was found. But there was heterogeneity due to other factors. The meta–analysis showed that, the sensitivity of f/t-PSA with the critical value of 0.15 for the diagnosis of prostate cancer with a t-PSA level of 4-10ng/mL was 75% (95%CI 70%-79%), and the specificity was 81% (95%CI 78%-84%). The area under SROC curve was 0.883 5, and the Q index was 0.814 0.
Conclusion  The f/t-PSA is a better index for diagnosing prostate cancer with t-PSA levels between 4 and 10ng/mL. And it is reasonable to consider 0.15 as a more suitable critical value.

Citation: GUO Xiaofan,XU Hainan,ZHANG Xiaoyu,WANG Hailong,SHI Jingpu. The Accuracy of f/t-PSA for Diagnosing Prostate Cancer with a t-PSA Level of 4-10ng/mL: A Systematic Review and Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2010, 10(10): 1164-1168. doi: 10.7507/1672-2531.20100564 Copy

  • Previous Article

    Diagnostic Value of MRI versus Bone Scan for Osseous Metastasis in Breast Cancer: A Meta-analysis
  • Next Article

    Autologous Stem Cell Transplantation after High-dose Chemotherapy in First-line Treatment of Follicular Lymphoma: A Meta-analysis